The end-stage kidney disease (ESKD) population receiving maintenance dialysis is highly vulnerable to the devastating consequences of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and associated coronavirus disease 2019 (COVID-19). Although uremia itself is associated with an immune-incompetent state, patients with ESKD are generally older and often have comorbid conditions that increase the risk for poor outcomes in COVID-19.1,2 To date, information on the clinical course of COVID-19 among the ESKD population is limited to single-center experiences and/or homogeneous populations.
No takes yet. Share an insight, caveat, or question.
Sim et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: